Abstract
We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial. Although the patient initially responded to therapy, RAD001 was discontinued after 32 weeks due to progression and fludarabine-based chemotherapy was started. The patient subsequently developed a rapidly fatal Epstein-Barr-virus-associated lymphoproliferative disorder, clonally unrelated to the CLL. The clinical course suggests caution when using newer immunosuppressive drugs for treatment of CLL, especially in the context of additional purine analog therapy.
Publication types
-
Case Reports
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Epstein-Barr Virus Infections / etiology*
-
Everolimus
-
Fatal Outcome
-
Female
-
Herpesvirus 4, Human / genetics
-
Herpesvirus 4, Human / isolation & purification*
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Lymphoproliferative Disorders / etiology*
-
Phosphoinositide-3 Kinase Inhibitors*
-
Protein Kinases*
-
Sirolimus / analogs & derivatives*
-
Sirolimus / therapeutic use
-
TOR Serine-Threonine Kinases
-
Vidarabine / analogs & derivatives
-
Vidarabine / therapeutic use
Substances
-
Immunosuppressive Agents
-
Phosphoinositide-3 Kinase Inhibitors
-
Everolimus
-
Protein Kinases
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Vidarabine
-
fludarabine
-
Sirolimus